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AbstractmT cell triggering can be achieved by monoclonal
antibodies (mAbs) specific for the CD3/TcR complex. In
the presence of appropriate costimulation and/or progres-
sion factors, such triggering permits the generation of
effector cells for immunotherapy protocols involving the
redirection of T cell lysis against tumor cells by mAbs
bispecific for anti-CD3/anti-tumor cells (bs-mAbs). Focus-
ing our analysis on the clinically relevant bs-mAb OC/TR,
we found that bs-mAbs generated with the same anti tumor
specificity, but two other anti-CD3 mAbs, TR66 and OKT3,
have the same and a significantly lower lytic potential,
respectively, compared with that of OC/TR. To evaluate the
relevance of the anti-CD3 component, we examined several
anti-CD3 mAbs with respect to binding parameters and the
ability to trigger T lymphocytes. Competitive binding
assays suggested that all anti-CD3 mAbs recognized the
same or overlapping epitopes, although mAbs BMA030
and OC/TR bound with lower avidity than did a CD3 (the
bivalent anti-CD3 mAb produced by the hybrid hybridoma
OC/TR), TR66 and OKT3, as determined by measurement
of the affinity constants. In all lymphocyte populations
examined, which included resting peripheral blood mono-
nuclear cells (PBMC), activated PBMC and T cell clones,
OKT3, BMA033 and OC/TR failed to mobilize Ca2+ with-
out cross-linking, whereas a CD3, in both murine and
murine-human chimeric versions, TR66 and BMA030,
did not require cross-linking. The ability to induce CD3
modulation was associated in part with the induction of
Ca2+ fluxes. Despite the differences in the behavior of these
mAbs in triggering the events that precede proliferation, all
of them ultimately led to expression of the IL-2 receptor
and to proliferation in T cells in the presence of accessory
cells. Our data suggest that anti-CD3 mAbs that bind more
rapidly (strong Ca2+ mobilizers) and more tightly under
physiological conditions are good candidates for retargeting
T cells in the bs-mAb clinical application.
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to inhibit mAb binding by 50%; PBMC, peripheral blood
mononuclear cells; r, recombinant; TAA, tumor-associated
antigen.
Introduction
TcR heterodimers provide T cells with the specificity for
cognate recognition of antigen within the MHC, but the cell
surface expression and function of the TcR are both
dependent on the associated CD3 complex [41]. The
physiological TcR-MHC/antigen interaction, together with
the cooperative interaction of accessory molecules, leads to
clonotypic T cell activation through several related steps,
beginning with second messenger generation and ending
with the development of effector functions. The same
biochemical events can be engaged in polyclonal T cell
populations by antibodies specific for framework epitopes
of the TcR or the invariant chains of the CD3 complex
[3, 32].
Triggering of any T cell, irrespective of its fine speci-
ficity, by anti-CD3 mAbs has been therapeutically exploited
by construction of bispecific mAbs (bs-mAb) in conjunc-
tion with a number of different anti-tumor-associated anti-
gen (TAA) mAbs. Engagement and cross-linking of the
TcR-CD3 complex alone may lead to a state of T cell
unresponsiveness (anergy) or even to cell death by apopto-
sis [16]. Thus, adoptive immunotherapy based on the use of
anti-CD3/anti-TAA bs-mAbs requires the ex vivo activation
N. Jacobs ? M.P. Moutschen ? J. Boniver
CHU Sart Tilman, Anatomie Pathologique, Lie`ge 1-4000, Belgium
S. Canevari ? A. Mazzoni ? D. Mezzanzanica ? D.R.M. Negri ?
O. Valota ? M.I. Colnaghi
Division of Experimental Oncology E, Istituto Nazionale Tumori,
Via Venezian 1, I-20133 Milano, Italy
Tel.: (39) –2–2390567; fax (39)–2–2362692
Cancer Immunol Immunother (1997) 44: 257 –264 Ó Springer-Verlag 1997
of T cells for effective anti-tumor reactions. Properly
activated T lymphocytes that are specifically retargeted to
tumor cells by bs-mAbs can lyse tumor cells and inhibit
their in vitro growth [25, 31]. This approach has resulted in
eradication of human tumors in xenotransplanted mice [14,
26]. Numerous anti-CD3 mAbs have been used to study the
activation of T cells [1, 11, 17, 20, 28– 30], but only a few
have been used to generate anti-tumor bs-mAbs [26, 31].
Several phase I trials have suggested the clinical potential
of anti-tumor/anti-CD3 bs-mAb [2, 4, 8, 9, 40], and at least
one phase II trial in ovarian carcinoma patients has demon-
strated the benefit of these reagents [6]. Using hybrid
hybridomas derived from the fusion of the same anti-
ovarian carcinoma hybridoma with two different anti-CD3
hybridomas (OKT3 and TR66) [10, 38] or immunized
spleen cells [10], we evaluated the relevance of the fine
binding specificity of the anti-CD3 component of the bs-
mAb in redirecting T cell-induced lysis. Since the three bs-
mAbs differed in cytolytic potential, the parental anti-CD3
mAbs and some others were examined for their ability to
trigger T lymphocytes activation. Our results show that
these mAbs behave differently in triggering the events that
precede proliferation, such as Ca2+ mobilization and CD3
modulation, but all of the mAbs tested ultimately lead to
expression of the IL-2 receptor and to proliferation of T
cells in the presence of progression factors.
Material and methods
Anti-CD3 antibodies
BMA030 (mIgG2a) and BMA033 (mIgG3) were kindly provided in
purified form by Dr. Kurrle (Behringwerke, Marburg, Germany).
OKT3 (mIgG2a) and TR66 (mIgG1) hybridomas were obtained from
the ATCC (Rockville, Md.) and kindly provided by Dr. A. Lanzavec-
chia (Basel Institute), respectively. Three anti-ovarian carcinoma/anti-
CD3 hybrid hybridomas, the trioma OC/TR (mIgG1) and the quad-
romas T3/OC1 (mIgG1/G2a) and T3/OC2 (mIgG1), derived from the
fusion of hybridoma MOv18 [15] with spleen cells of a mouse
immunized with human T cells and hybridomas OKT3 and TR66,
respectively, were also used [10]. OC/TR has been fully characterized
and used in preclinical and clinical studies [3, 6, 13, 23]. The mAbs
were purified from mouse ascitic fluid or cell culture supernatant by
affinity chromatography on insolubilized protein A according to their
isotype. The bs-mAbs and, in the case of the mAb produced by the
trioma OC/TR, the anti-CD3 bivalent component (referred to below as
a CD3) were fractionated on a hydroxylapatite HPLC column as
described elsewhere [23]. Their purity and integrity was confirmed
by SDS-PAGE and isoelectrofocusing using the automated micropro-
cessor-driven Phastsystem (Pharmacia LKB Biotechnology, Uppsala,
Sweden), by analytical gel filtration, and by FACScan (Becton Dick-
inson, Erembodegem, Belgium) analysis of the target cells. Chi-a CD3,
obtained by chimerizing the variable regions of the a CD3 with the
human L- and IgG1-constant regions [18], was kindly provided in
purified form by Dr. L. Coney (Centocor, Malvern, Pa.) All mAbs were
kept at 4° C in sterile saline and were used as entire IgG molecules.
Preparation and culture of lymphocytes
PBMC were obtained from heparinized peripheral blood of healthy
adult donors by centrifugation on Lymphoprep (Nycomed, Oslo, Nor-
way), washed three times, and counted. For evaluation of mAb-binding
characteristics, PBMC were activated with PHA (Wellcome, Dartford,
UK) (1m g/ml) and stimulated with 100 U/ml human recombinant (r)
IL-2 (kindly provided by Glaxo Institute for Molecular Biology,
Geneva, Switzerland) as already described [22]. For evaluation of
Ca2+ fluxes, PBMC were stimulated for 4 days with 50 U/ml rIL-2 plus
10 ng/ml mAb BMA030. Two alloreactive T-cell clones (DM3 and
DM13) were used in Ca2+ flux analysis and for evaluation of bs-mAb
cytotoxic activity. Both clones were restimulated every 2 weeks with
1m g/ml PHA and irradiated (3,000 R) allogeneic PBMC and stimulated
with rIL-2 (25 U/ml). The culture medium consisted of RPMI 1640
(Gibco, Ghent, Belgium) supplemented with 1% non-essential amino
acids (Gibco), 1 mM sodium pyruvate (Gibco), 30 U/ml penicillin-
streptomycin (Gibco) and 5% pooled heat-inactivated human AB
serum.
Assay of bs-mAb cytotoxic activity
Cytotoxicity was determined in a standard 4-h 51Cr-release assay.
Ovarian carcinoma IGROV1 cells were incubated for 1 h at 37° C
with 100 m Ci Na251CrO4/106 cells (ICN Biomedicals, Milan, Italy).
After washing, cells (5000/well) were seeded in triplicate in U-shaped
96-well plates with DM13 alloreactive T cell clone at an effector-to-
target cell ratio of 10:1 and the indicated amount of bs-mAb in a final
volume of 0.2 ml/well. After 4 h of incubation, 0.1 ml/well of
supernatant was withdrawn and radioactivity measured in a b -counter.
Spontaneous release of 51Cr, determined in cells incubated with
medium alone, was always 520%. Maximum 51Cr release was
measured in cells lysed in 1% NP-40. SEM of triplicates never
exceeded 5–10%.
Percent specific lysis was calculated as
100  Experimental release cpm ÿ spontaneous release cpm
Maximum release cpm ÿ spontaneous release cpm
Anti-CD3 mAb binding assays
Based on their sensitivity to labeling procedures, mAbs a CD3,
BMA030, TR66 and OC/TR were labeled with 125I (Amersham,
Aylesbury, UK) by lactoperoxidase-catalyzed iodination [12] to a
mean specific activity of 8.4 m Ci/g. OKT3 was labeled by the
Bolton-Hunter method to a final specific activity of 4.4 m Ci/g.
The Kaff and number of sites recognized by the anti-CD3 mAbs
were evaluated by Scatchard analysis. Activated PBMC (2 · 105/well in
0.05 ml RPMI-1640 plus 1% FCS) were incubated for 3 h at 0° C with
serial dilutions of 125I-mAb. After three washes with cold buffer (PBS
plus BSA, 0.03% w/v), cell-bound radioactivity was measured directly
in a counter. Background was determined in the presence of a 100-fold
excess of cold mAb. For competition assays, activated PBMC were
seeded at 2 · 105 cells per well in 0.05 ml of RPMI-1640,1% FCS, in
the presence of a fixed amount of 125I-mAb (5 · 105 cpm/well) and
different concentrations of competitor. After incubation for 3 h at 0° C
or 37 ° C, cells were washed three times and assessed directly for
radioactivity in a g -counter. The dose of cold competitor required to
inhibit radiolabeled mAb binding by 50% (IC50) was extrapolated from
dose-response curves.
Assays of cytoplasmic free Ca2+
After addition of 3 m l of 20% (v/v) Plutronic F-127 (Molecular Probes,
Eugene, Ore.), lymphocytes (107 in 1 ml of Hank’s solution, Gibco)
were loaded with 3 M fluo-3/AM (Molecular Probes) and incubated for
20 min in the dark at 37° C. After dilution (1/5) in HBSS containing 1%
FCS and a further 45 min incubation at 37° C, cells were washed three
times and resuspended at a concentration of 1–2 · 106 cells/ml in
Hepes-buffered saline (Sigma, St. Louis, Mo.). Before flow cytometry,
cells were incubated for 10 min at 37° C in a water bath. Cells were
stimulated by anti-CD3 mAbs (2 m g/ml) and analyzed on a Facscan. In
all experiments, 8 m g/ml of rabbit anti-mouse Ig (Chemicon, Temecula,
Calif.) was added to crosslink the prebound anti-CD3 mAb before re-




Responder donors PBMC able to bind and to proliferate equally well in
the presence of anti-CD3 IgG1 and IgG2a mAbs [20] were selected.
PBMC (1.25 · 106 cells/ml) were cultured for 4 days in the presence of
50 U/ml of human rIL-2. On days 2 and 4 of culture, cells were plated
in triplicate in 96-well U-bottomed plates at 104 cells/well in 200 m l of
medium. 3H-Thymidine (25 m l, 0.4 mCi, Dupont NEN, Dreieich,
Germany) was added to each well, and after 4 h cells were harvested
with a cell harvester (Skatron, Lier, Norway) on glassfiber filters,
whereupon 3H-thymidine incorporation was determined by scintillation
counting (1500 TriCarb Packard).
Immunofluorescence and flow cytometry
PBMC stimulated for 1–4 days with anti-CD3 mAb and rIL-2
(0.5 · 106 cells) were incubated on ice with 25 m l of goat anti-mouse
Ig-FITC (Immunotech, Marseille, France), anti-CD3-FITC (B-B11,
IQP, Groningen, The Netherlands), or anti-CD25-PE (Dako, Denmark).
After washing, cells were analyzed for fluorescence intensity on a
Facstar+ (Becton Dickinson) with Lysis II software.
Statistical analysis
Data were analyzed using the Student’s t-test, Mann-Whitney or an
ANOVA test (Instat, GraphPad software).
Results
Anti-ovarian carcinoma/anti-CD3 bs-mAb induce different
cytotoxicity
We showed previously that T3/OC1 (MOv18 · OKT3)
mediates a lytic activity lower than that induced by OC/
TR (MOv18 · a CD3) [13]. Using a different T cell clone,
we confirmed that the T3/OC1 was less efficient than OC/
TR and T3/OC2 (MOV18 · TR66) bs-mAbs, which are
raised with different anti-CD3 specificities, in retargeting
(Fig. 1). Indeed, in each test and at both bs-mAb concen-
trations (100 and 1 ng/ml), the lysis mediated by the bs-
mAb with OKT3 was significantly lower.
Anti-CD3 mAbs have different binding properties
To determine whether the affinity and avidity of different
anti-CD3 mAbs might determine the different cytotoxic
potential of bs-mAb, binding properties of the three paren-
tal anti-CD3 mAbs ( a CD3, OKT3, TR66), another anti-
CD3 mAb (BMA030) and bs-mAb OC/TR were assessed
by Scatchard analysis and competition assays. The experi-
ments were initially performed at 0 ° C to ensure a high
binding level. Scatchard analysis of the binding data re-
vealed comparable Kaff values for a CD3 (7.4 · 108 M –1),
OKT3 (7 · 108 M –1) and TR66 (3.6 · 10–8 M), and 4 – 10
times lower values for BMA030 (0.8 · 108 M –1) (Fig. 2)
and OC/TR (1 · 108 M) (not shown). Competitive binding
assays at 0 ° C suggested that all anti-CD3 mAbs recognized
the same or overlapping epitopes (see Fig. 3 for a repre-
sentative experiment of a CD3 competition), although OC/
TR and BMA030 bound with lower avidity, than a CD3,
TR66 and OKT3.
Competition experiments performed at 37 ° C to evaluate
binding properties in physiological conditions (Fig. 3) re-
vealed an inhibition induced by each anti-CD3 that re-
sembled the pattern observed at 0 ° C, despite an increase in
the IC50 values, which was particularly evident for
BMA030 (IC50=12.9 nM at 0° C and 264 nM at 37 ° C)
and OKT3 (IC50=8.5 at 0° C and 794 nM at 37 ° C).
Stimulation by different anti-CD3 mAb induces different
calcium fluxes
The calcium response after stimulation with seven different
anti-CD3 mAb without further cross-linking was studied on
different cell populations: resting PBMC, BMA030-acti-
vated PBMC and CD8+ or CD4+ T cell clones (Table 1). In
all experiments, BMA030, TR66, a CD3 and chi- a CD3
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Fig. 1mAnti-ovarian carcinoma/anti-CD3 bs-mAb redirected lysis of
IGROV1 cells by a CTL clone in a 4-h 51Cr-release assay. DM13 CTL
clone cells were used at an effector to-target cell ratio of 10:1 in the
presence of 100 ng/ml& or 1 ng/ml& of whole bs-mAb. Lysis in the
absence of bs-mAb or in the absence of CTL was less than 5%. Data
are reported as mean+SEM of 3–5 independent experiments
Table 1mCalcium response in different lymphocyte preparations after
stimulation with different anti-CD3 mAb
Anti-CD3 Calcium responsea in
mAb







BMA030 193+21 (5)b 171+24 (5) 387+83 (2) 148+23 (4)
TR66 186+13 (6) 172+17 (4) 384+51 (3) 147+19 (4)
OKT3 122+ 6 (5) 99+ 4 (3) 127+22 (2) 90+ 4 (3)
OC/TR 125+ 9 (4) 102+ 4 (4) 171+12 (2) 99+ 6 (4)
a CD3 218+11 (2) 278 (1) 455 (1) 163+17 (2)
chi- a CD3 198+11 (3) – 355 (1) 137+22 (2)
BMA033 118 (1) 98 (1) 96 (1) 96 (1)
a Evaluated as free cytoplasmic Ca2+ levels in fluo-3-loaded cells.
Data are reported as: (mean fluorescence after addition of anti-CD3/
mean fluorescence of baseline) · 100
b Mean + SD (number of experiments)
mAbs induced calcium mobilization, whereas OKT3,
BMA033 and OC/TR generated only low or no detectable
calcium fluxes. Figure 4A shows representative FACS
profiles on resting PBMC. A higher (6 m g/ml) or lower
(10 ng/ml) concentration of OKT3 did not generate a Ca2+
response at the levels obtained with TR66 or BMA030
(data not shown). The extent of Ca2+ increase was depen-
dent on the T cell type and activation status, and the
responses were highest in the CD8+ T cell clone, but the
various anti-CD3 mAb gave a similar cline of response with
all the cell types used. After cross-linking with rabbit anti-
mouse or anti-human IgG, the Ca2+ response became
comparable for all anti-CD3 mAbs (Fig. 4B). By comparing
monovalent OC/TR with the murine and the chimeric
versions of the bivalent parental a CD3 and by cross-linking
with anti-mouse or anti-human Ig, we confirmed that
binding valency plays a role in inducing Ca2+ mobilization.
However, bridging to monocytes present in the PBMC
population by mAb or bs-mAb Fc portion did not induce
Ca2+ mobilization, perhaps because bridging occurs later or
because the number of monocytes is insufficient.
OC/TR and BMA033 do not induce CD3 modulation
Modulation of the CD3 molecule was evaluated on resting
PBMC of responder donors (see “Materials and methods”).
Cells were cultured in the presence of rIL-2 and soluble
anti-CD3 mAb (10 ng/ml) and analyzed for CD3 expression
and the residual presence of the anti-CD3 mAb on the cell
surface from day 1 to day 4 (Table 2). At the concentrations
tested, there was no competition between the anti-CD3 used
for detection and the anti-CD3 mAb used for stimulation
(data not shown). Down-regulation of CD3 was observed
after 24 h stimulation with TR66, BMA030, a CD3 and chi-
a CD3, but not with OC/TR or BMA033; OKT3 induced
intermediate down-regulation (Fig. 5A). The modulation
pattern by the mAbs was highly reproducible, except for
BMA030, with PBMC from different donors (Table 2).
CD3 expression returned to initial values on day 4, despite
the continuous presence of the anti-CD3 mAbs during the
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Fig. 2mScatchard plots of 125I-anti-CD3 mAb binding on human
activated PBMC. Inset binding plots. Statistical analysis of the curves:
a CD3, R2=0.95195 (P50.0001); OKT3 R2=0.99451 (P50.0001);
TR66, R2=0.97066 (P50.0001); BMA030 R2=0.9188 (P50.05)
induction period. The anti-CD3 mAbs were detectable on
the cell surface by staining with an anti-mouse or anti-
human Ig-FITC on day 1 (Fig. 5B).
All anti-CD3 mAbs induce cell proliferation and IL-2
receptor expression
Under the culture conditions described above, the levels of
cell activation induced by the soluble anti-CD3 mAb were
compared by measuring cell proliferation and the expres-
sion of the IL-2 receptor (CD25) in three independent
experiments. On day 2, a proliferative response was ob-
served with all anti-CD3 mAbs, but the bs-mAb OC/TR
was significantly less potent in inducing proliferation than
was its parental a CD3 (Fig. 6A). After 4 days of culture, a
similar proliferative response was observed for all anti-CD3
mAbs (Fig. 6B). Results were similar for the expression of
the IL-2 receptor. A significantly lower percentage of
CD25+ cells was observed in culture with OC/TR on day
2 (Fig. 6A), but this percentage increased to near that with
other anti-CD3 mAbs on day 4 (Fig. 6B).
Discussion
The significant clinical potential of bs-mAbs containing
anti-CD3 in retargeting T cell cytotoxicity against tumor
cells led us to evaluate the possible correlation between
their cytotoxic efficiency and the binding and activating
potential of the parental anti-CD3 mAbs. We focused our
analysis on the bs-mAb OC/TR, which is now being used in
clinical trials [4– 6]. Comparison of the parental mAb
a CD3 with several other anti-CD3 mAbs showed that all
the tested anti-CD3 mAbs ultimately led to full T cell
activation in a system in which progression factors are
provided. This was true despite an apparent inability of OC/
TR, OKT3 and BMA033 to trigger Ca2+ mobilization.
Recently, Zhu and Carter [42] demonstrated a direct corre-
lation between antigen-binding efficiency and late T cell
activation events in a panel of humanized variants of the
anti-CD3 mAb UCHT1. We analyzed the influence of anti-
CD3 mAb-binding parameters on early (Ca2+ mobilization)
and intermediate-late (CD3 modulation, CD25 expression
and proliferation) events.
Our use of the calcium probe fluo-3 in flow cytometry to
measure the increase in cytoplasmic Ca2+ [37] permitted a
semi-quantitative evaluation with clear-cut advantages over
spectrofluorimetry. Previous studies, conducted mainly
with probes that require ultraviolet light [1, 7, 11, 17, 20,
24, 27– 30], have led to conflicting conclusions about a
requirement for cross-linking and/or bridging of the TcR-
CD3 complex in increasing the cytosolic Ca2+ concentra-
tion. Several variables, such as the type of T cell population
studied or the concentration, fine binding specificity, bind-
ing affinity or valency of the mAb, might account for the
discrepant results.
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Fig. 3mBinding properties of different anti-CD3 mAb. 125I-a CD3 mAb
(10 nM) binding to human activated PBMC competed with titrated
doses of unlabeled homologous or heterologous mAb, as described in
Materials and methods for each radiolabeled mAb at 0° C or at 37 ° C.
Competing mAb: TR66 (&); OKT3 (*); a CD3 (!); BMA030 (r);
OC/TR (m). Data are representative of the experiments performed with
radiolabeled TR66, OKT3, BMA030 and OC/TR with similar results
Table 2mCD3 modulation induced by different anti-CD3 mAbs on
PBMC
CD3 expression at daya
Culture condition 1 2 3 4
Control 1.00 1.00 1.00 1.00
IL-2 1.01+0.08 1.07+0.09 1.25+0.28 1.06+0.09
IL-2 + BMA030 0.52+0.33 0.71+0.53 1.03+0.65 1.15+0.54
IL-2 + TR66 0.30+0.06 0.45+0.28 1.07+0.17 0.91+0.31
IL-2 + OKT3 0.58+0.16 0.74+0.18 1.15+0.23 1.16+0.30
IL-2 + OC/TR 0.91+0.10 1.06+0.11 1.39+0.33 1.25+0.19
IL-2 + a CD3 0.22+0.12 0.74+0.59 1.11+0.83 1.19+0.54
IL-2 + chi a -CD3 0.29+0.07 0.46+0.127 1.08+0.18 1.27+0.22
IL-2 + BMA033 0.94+0.05 0.92+0.06 1.20+0.30 1.28+0.22
a Data are mean + SEM of three independent experiments and are
expressed as: mean fluorescence in presence of anti-CD3/mean fluor-
escence in control cells
All of our anti-CD3 mAbs competed with each other in
binding assays, and the amounts required at 0 ° C to obtain
the same inhibition were clearly related to their binding
affinity. These data imply that the mAbs tested are directed
to the same or spatially close epitopes. Previous analysis
[34] identified at least three epitope groups on human CD3
through which T cell activation by anti-CD3 mAb can
proceed. OKT3, TR66 and BMA030, which belong to the
same CD3 recognition group but bind with a different
avidities, differ in their ability to promote Ca2+ mobiliza-
tion. Our data suggest that the fine binding specificity of
anti-CD3 mAb per se plays only a minor part in triggering
early activation events, although any firm conclusions await
further structure-function analyses.
No clear correlation between the ability to trigger Ca2+
mobilization and Kaff values was observed, at least in the
cases of OKT3 and BMA030. However, our Kaff determi-
nations, like most of those reported in the literature, were
performed at 0 – 4° C, whereas Ca2+ mobilization studies
were conducted at 37 ° C. Competition analysis at 37 ° C,
which enables evaluation of binding strength under physi-
ological conditions (on- and off-rate equilibrium), has
demonstrated that both OKT3 and BMA030 have an inter-
mediate ability to compete with the 125I-a CD3 binding,
which was less than the competition exerted by TR66 and
homologous mAb.
OKT3 and BMA033 mAbs and OC/TR bs-mAb that
were virtually unable to promote Ca2+ mobilization during
the first minutes of incubation were also less able or at least
slower to promote the modulation of CD3 molecules and
expression of CD25. However, all of the mAbs and the bs-
mAb OC/TR ultimately induced proliferation, although
with a slower kinetics. These data indicate that early Ca2+
mobilization is not a sufficient predictor of final activating
ability and that full T cell activation can occur even in the
absence of a detectable Ca2+ increase, due possibly to
persistent but undetectable Ca2+ mobilization, or to the
activation of another signal transduction pathway. The
requirement for TcR/CD3 cross-linking in T cell activation
is difficult to extrapolate to the physiological interaction
between the TcR and the MHC-peptide complex displayed
on the surface of antigen-presenting cells. Indeed, this
interaction takes place with as few as 100 complexes and
has low affinity and a high off-rate [35]. A model of TcR
serial triggering was recently proposed [36] according to
which the high off-rate of the TcR is instrumental because it
allows a single peptide-MHC complex to engage many
TcRs in successive rounds of ligation, triggering and dis-
sociation. According to this model, a higher affinity could
result in less stimulation because the lower off-rate may
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Fig. 4mCytoplasmic free Ca2+ levels in response to anti-CD3 mAb
binding A alone and B after cross-linking. Resting PBMC loaded with
fluo-3 were stimulated with BMA030, TR66, OKT3, a CD3 and
OC/TR (2 m g/ml) at the time indicated by the arrow (A) and subse-
quently cross-linked with a rabbit anti-mouse Ig (RAM, 8 m g/ml) (B).
FACS contour plots of one representative experiment are reported. The
time intervals were 512 s (A) and 205 s (B)
Fig. 5A, BmDegree of CD3 modulation by different anti-CD3 mAbs. A
After 1 day of culture in medium alone (control), or in the presence of
rIL-2 or rIL-2 + anti-CD3 mAbs (10 ng/ml), CD3 expression was
measured using an anti-CD3-FITC mAb. B Staining cells with FITC-
goat anti-mouse Ig or anti-human Ig in the case of chi- a CD3 showed
residual anti-CD3 mAb used for the stimulation. Data are from a single
experiment representative of three performed with PBMC from differ-
ent donors (see Table 2)
prevent TcR reusage. In the case of surrogate antigenic
stimulation through anti-CD3 mAbs, the number of con-
current interactions is 1000 times that between the TcR and
the MHC-peptide complex. Moreover, TcR signaling char-
acteristically requires that Ca2+ mobilization be sustained
for at least 30 min to induce proliferation and cytokine
production [21, 39]. Thus, high binding affinity of anti-CD3
mAbs might not be detrimental, provided that their off-rates
are low enough to sustain prolonged Ca2+ mobilization.
In conclusion, we suggest that the best candidates for
anti-tumor/anti-CD3 bs-mAb generation are anti-CD3
mAbs, such as a CD3 and TR66, which bind rapidly (strong
Ca2+ mobilizers) and tightly (good competitors at 37 ° C)
under physiological conditions. These mAbs, even in
monovalent form, as in the bs-mAb configuration, can be
expected to promote and sustain full activation in vivo.
Indeed, the higher in vitro cytolytic potential of bs-mAb
generated with CD3 and TR66 than of anti-TAA/OKT3 bs-
mAb [13] (present report) supports this prediction. On the
other hand, the in vivo use of bs-mAb with high promoting
ability must be considered with caution in light of the
finding that F(ab9)2 of the OC/TR bs-mAb, when injected
i.v. even at dose of 0.2 mg, induced a generalized in vivo
activation with severe side effects [2, 33] similar to those
induced by 5 mg of OKT3 [19]. Thus, treatment protocols
with autologous ex vivo-activated lymphocytes coated with
OC/TR must be appropriately designed [5] to avoid toxicity
while retaining maximum anti-tumor bs-mAb retargeting
potential.
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